Clinical Approach to Upper Gastrointestinal Bleeding
Comprehensive Practical Framework1. Symptom Overview
Understanding the clinical significance and classification of Upper Gastrointestinal Bleeding
Upper gastrointestinal bleeding is a common medical emergency that accounts for approximately 300,000 to 350,000 hospitalizations annually in the United States. It represents one of the most frequent gastrointestinal emergencies encountered in clinical practice, with an annual incidence of approximately 50 to 150 cases per 100,000 population. Despite advances in endoscopic therapy and critical care, mortality remains significant at 2% to 10% overall, rising to 20% to 30% in patients with variceal bleeding. The economic burden is substantial, with each hospitalization costing an average of $5,000 to $20,000 depending on severity and interventions required.
Definition
Upper gastrointestinal bleeding refers to blood loss originating from a source proximal to the ligament of Treitz (the suspensory ligament of the duodenum at the duodenojejunal junction). This anatomical landmark separates upper from lower gastrointestinal bleeding and includes bleeding from the esophagus, stomach, and duodenum. Upper gastrointestinal bleeding may present as hematemesis (vomiting of blood), coffee-ground emesis, melena (black tarry stools), or in cases of massive hemorrhage, hematochezia (bright red blood per rectum).
Classification by Severity
| Category | Clinical Features | Hemodynamic Status | Clinical Significance |
|---|---|---|---|
| Mild | Occult blood loss, minor melena, minimal symptoms | Hemodynamically stable, heart rate less than 100 bpm, systolic blood pressure greater than 100 mmHg | Outpatient workup may be appropriate in select cases; low mortality risk |
| Moderate | Overt hematemesis or melena, symptomatic anemia | Mild tachycardia, orthostatic hypotension, estimated blood loss 15% to 30% | Requires hospitalization, monitoring, and urgent endoscopy within 24 hours |
| Severe (Massive) | Large volume hematemesis, syncope, altered mental status | Hypotensive (systolic blood pressure less than 90 mmHg), tachycardic (heart rate greater than 120 bpm), estimated blood loss greater than 30% | Life-threatening emergency; requires immediate resuscitation, ICU admission, and emergent endoscopy |
Classification by Etiology
Non-Variceal Bleeding (80% to 90%)
Bleeding from sources other than esophageal or gastric varices. This includes peptic ulcer disease (most common, accounting for 35% to 50% of cases), erosive gastritis or esophagitis, Mallory-Weiss tears, malignancy, Dieulafoy lesions, and angiodysplasia. Non-variceal bleeding generally has a lower mortality rate (2% to 5%) and better response to endoscopic therapy.
Variceal Bleeding (10% to 20%)
Bleeding from esophageal or gastric varices secondary to portal hypertension, most commonly due to cirrhosis. Variceal bleeding carries significantly higher mortality (15% to 30% at 6 weeks) and requires specific management including vasoactive medications, antibiotic prophylaxis, and often band ligation or sclerotherapy. Recurrence rates are high without secondary prophylaxis.
Classification by Presentation
| Presentation | Description | Clinical Implications |
|---|---|---|
| Hematemesis | Vomiting of fresh red blood or blood clots; indicates active or recent bleeding | Suggests proximal source (esophagus or stomach); bright red blood indicates rapid bleeding; coffee-ground appearance suggests slower bleeding with gastric acid conversion of hemoglobin |
| Coffee-Ground Emesis | Vomited blood that has been partially digested, appearing dark and granular | Indicates blood has been in contact with gastric acid; may represent slower or intermittent bleeding; still requires urgent evaluation |
| Melena | Black, tarry, foul-smelling stools due to digested blood | Requires as little as 50 to 100 mL of blood in the upper gastrointestinal tract; blood typically in the gut for at least 8 hours; can persist for several days after bleeding stops |
| Hematochezia | Passage of bright red or maroon blood per rectum | Usually indicates lower gastrointestinal source, but can occur with massive upper gastrointestinal bleeding (greater than 1000 mL) with rapid transit; associated with hemodynamic instability when from upper source |
| Occult Bleeding | Blood loss detectable only by fecal occult blood testing or iron deficiency anemia | May indicate chronic slow bleeding from erosive disease, malignancy, or vascular malformations; requires investigation but typically non-urgent |
Risk Stratification Scores
| Scoring System | Components | Clinical Use |
|---|---|---|
| Glasgow-Blatchford Score | Blood urea nitrogen, hemoglobin, systolic blood pressure, heart rate, melena, syncope, hepatic disease, cardiac failure | Pre-endoscopy score; score of 0 to 1 identifies low-risk patients who may be suitable for outpatient management; higher scores predict need for intervention |
| Rockall Score | Age, shock, comorbidities, diagnosis, and stigmata of recent hemorrhage (requires endoscopy for complete score) | Predicts rebleeding and mortality; complete score calculated after endoscopy; pre-endoscopy score useful for initial risk assessment |
| AIMS65 Score | Albumin less than 3.0 g/dL, INR greater than 1.5, altered mental status, systolic blood pressure less than 90 mmHg, age greater than 65 years | Simple bedside score predicting in-hospital mortality; each factor scores 1 point; score of 2 or more associated with significantly increased mortality |
Key Concept: The “Big Four” Causes of Upper Gastrointestinal Bleeding
Four conditions account for approximately 80% to 90% of all cases of upper gastrointestinal bleeding:
- Peptic ulcer disease (35% to 50%) — gastric and duodenal ulcers, often associated with Helicobacter pylori infection or nonsteroidal anti-inflammatory drug use
- Erosive disease (15% to 25%) — erosive gastritis, esophagitis, and duodenitis
- Esophageal and gastric varices (10% to 20%) — secondary to portal hypertension
- Mallory-Weiss tears (5% to 15%) — mucosal lacerations at the gastroesophageal junction from forceful retching
2. Pathophysiology and Mechanisms
Understanding the underlying mechanisms of Upper Gastrointestinal Bleeding
Understanding the pathophysiology of upper gastrointestinal bleeding requires knowledge of the normal protective mechanisms of the gastrointestinal mucosa and the various ways these defenses can be breached. The gastrointestinal tract maintains mucosal integrity through a balance of aggressive factors (acid, pepsin, bile, and Helicobacter pylori) and defensive factors (mucus-bicarbonate barrier, epithelial cell turnover, mucosal blood flow, and prostaglandins). Disruption of this balance leads to mucosal injury and bleeding.
Normal Mucosal Defense Mechanisms
| Defense Layer | Component | Function |
|---|---|---|
| Pre-Epithelial | Mucus-bicarbonate layer | Creates an unstirred layer that traps bicarbonate, maintaining a neutral pH at the epithelial surface despite luminal acid |
| Epithelial | Tight junctions, rapid cell turnover, surface phospholipids | Forms a physical barrier; epithelium regenerates every 3 to 5 days; phospholipids create hydrophobic surface layer |
| Sub-Epithelial | Mucosal blood flow, prostaglandins, growth factors | Blood flow removes back-diffused acid and provides nutrients; prostaglandins stimulate mucus and bicarbonate secretion and maintain blood flow |
| Vascular | Submucosal arterial plexus, microcirculation | Provides oxygen and nutrients; removes waste products; delivers immune cells; critical for tissue healing |
Mechanisms of Bleeding by Etiology
Peptic Ulcer Disease
Mechanism: Erosion through the mucosal barrier into the submucosa and muscularis, exposing submucosal vessels. Deep ulcers can erode into larger arteries (especially the gastroduodenal or left gastric artery).
Key factors: Helicobacter pylori infection (disrupts mucus layer, induces inflammation), nonsteroidal anti-inflammatory drugs (inhibit protective prostaglandins), excess acid production.
Variceal Bleeding
Mechanism: Portal hypertension (greater than 10 to 12 mmHg) causes formation of portosystemic collaterals. Esophageal and gastric varices develop as dilated, thin-walled vessels with high wall tension predisposing to rupture.
Key factors: Cirrhosis (most common cause), variceal size, portal pressure gradient, presence of red wale marks, and ongoing alcohol use.
Mallory-Weiss Tears
Mechanism: Forceful retching or vomiting causes a sudden increase in intra-abdominal pressure, creating longitudinal mucosal lacerations at the gastroesophageal junction where the mucosa is thinner.
Key factors: Preceding retching (often alcohol-induced), hiatal hernia, coughing, straining, or any cause of increased abdominal pressure.
How Specific Conditions Cause Bleeding
| Condition | Pathophysiological Mechanism | Treatment Implication |
|---|---|---|
| Peptic ulcer disease | Mucosal breach allows acid and pepsin to erode deeper layers; visible vessel at ulcer base is an exposed artery with pseudoaneurysm formation; adherent clot represents organized thrombus over bleeding point | Proton pump inhibitor therapy reduces acid, promotes healing and clot stability; endoscopic therapy targets the bleeding vessel directly; Helicobacter pylori eradication prevents recurrence |
| Esophageal varices | Increased portal pressure transmitted to thin-walled collateral vessels; Laplace’s law: wall tension = pressure × radius / wall thickness; large varices with high pressure and thin walls are at highest risk of rupture | Vasoactive drugs (octreotide, terlipressin) reduce portal pressure; band ligation mechanically obliterates varices; TIPS reduces portal pressure gradient; non-selective beta-blockers prevent recurrence |
| Erosive gastritis | Superficial mucosal injury from direct toxic effect (alcohol, NSAIDs), stress-induced mucosal ischemia, or bile reflux; multiple small bleeding points rather than single large vessel | Remove offending agent; proton pump inhibitor therapy; stress ulcer prophylaxis in critically ill patients; typically self-limited with supportive care |
| Dieulafoy lesion | Abnormally large submucosal artery (1 to 3 mm diameter) that fails to taper as it approaches the mucosa; minimal overlying mucosal defect; arterial bleeding is brisk and intermittent | Endoscopic therapy (combination of thermal and mechanical methods); lesion can be difficult to identify when not actively bleeding; angiographic embolization if endoscopy fails |
| Gastric antral vascular ectasia | Dilated mucosal capillaries in a characteristic pattern (watermelon stomach); associated with cirrhosis and systemic sclerosis; chronic slow blood loss rather than acute hemorrhage | Argon plasma coagulation of ectatic vessels; multiple sessions often required; iron supplementation and transfusion for chronic blood loss |
| Aortoenteric fistula | Direct communication between the aorta (usually a prosthetic graft) and the duodenum; initial herald bleed often followed by massive exsanguinating hemorrhage | Surgical emergency; requires graft removal and aortic reconstruction; high mortality if not recognized promptly; always consider in patients with prior aortic surgery |
| Upper gastrointestinal malignancy | Tumor neovascularization with friable, abnormal vessels; tumor necrosis and ulceration; invasion into larger blood vessels in advanced disease | Endoscopic palliation with thermal therapy or clips; radiation therapy for hemostasis; surgery or interventional radiology for refractory bleeding |
Role of Coagulation and Hemostasis
Normal Hemostatic Response
- Primary hemostasis: Platelet adhesion and aggregation at site of vascular injury
- Secondary hemostasis: Coagulation cascade activation leading to fibrin clot formation
- Clot stabilization: Cross-linking of fibrin by factor XIII
- Clot retraction: Platelet-mediated contraction consolidates the clot
Factors Impairing Hemostasis
- Antiplatelet agents: Aspirin, clopidogrel inhibit platelet function
- Anticoagulants: Warfarin, direct oral anticoagulants impair clot formation
- Liver disease: Decreased synthesis of clotting factors and thrombocytopenia
- Uremia: Platelet dysfunction in renal failure
- Gastric acid: pH less than 6 impairs clot stability and platelet aggregation
Often Overlooked Mechanism: The Role of Gastric pH in Hemostasis
Clot formation and stability are critically dependent on gastric pH. At pH less than 6, platelet aggregation is impaired and pepsin (which is active at low pH) degrades fibrin clots. This explains why high-dose proton pump inhibitor therapy is essential in upper gastrointestinal bleeding: maintaining gastric pH above 6 allows stable clot formation over bleeding vessels. Continuous intravenous proton pump inhibitor infusion maintains pH above 6 in more than 90% of patients, compared to intermittent bolus dosing which may be less effective at maintaining consistent acid suppression.
Physiological Response to Blood Loss
| Blood Loss | Compensatory Mechanisms | Clinical Signs |
|---|---|---|
| Class I (up to 15%, less than 750 mL) | Minimal sympathetic activation; transcapillary refill begins to restore intravascular volume | Minimal tachycardia; blood pressure, respiratory rate, and mental status normal; urine output greater than 30 mL/hour |
| Class II (15% to 30%, 750 to 1500 mL) | Increased sympathetic tone; catecholamine release causes vasoconstriction and increased heart rate; activation of renin-angiotensin-aldosterone system | Tachycardia (100 to 120 bpm); narrowed pulse pressure; anxiety; delayed capillary refill; urine output 20 to 30 mL/hour |
| Class III (30% to 40%, 1500 to 2000 mL) | Maximal sympathetic compensation; tissue hypoperfusion despite vasoconstriction; anaerobic metabolism and lactic acidosis begin | Marked tachycardia (greater than 120 bpm); hypotension; tachypnea; confusion; cool, pale extremities; urine output 5 to 15 mL/hour |
| Class IV (greater than 40%, greater than 2000 mL) | Compensatory mechanisms failing; cardiovascular collapse imminent without aggressive resuscitation | Severe tachycardia or bradycardia; profound hypotension; negligible urine output; lethargy or unconsciousness; imminent death |
Important Concept: Hemoglobin as a Late Marker
Initial hemoglobin levels can be misleading in acute gastrointestinal bleeding. Hemoglobin concentration is a ratio of red cell mass to plasma volume. In acute hemorrhage, both red cells and plasma are lost proportionally, so the hemoglobin concentration may initially appear normal despite significant blood loss. It takes 24 to 72 hours for transcapillary refill and intravenous fluid administration to expand the plasma volume and reveal the true extent of red cell loss. Therefore, clinical assessment of hemodynamic status and ongoing signs of bleeding are more reliable early indicators of severity than the initial hemoglobin level.
3. History Taking
A comprehensive approach to eliciting the Upper Gastrointestinal Bleeding history
Red Flags — Require Urgent Evaluation
- Hemodynamic instability — syncope, presyncope, orthostatic symptoms suggest significant blood loss
- Large volume hematemesis — bright red blood or large clots indicate active arterial bleeding
- Ongoing visible bleeding — continued hematemesis or hematochezia despite resuscitation
- Altered mental status — confusion or decreased consciousness suggests severe hypovolemia or hepatic encephalopathy
- Known or suspected varices — history of cirrhosis, portal hypertension, or prior variceal bleeding carries high mortality
- Anticoagulant use — warfarin, direct oral anticoagulants, or heparin increase bleeding severity and complicate management
- Prior aortic surgery — aortoenteric fistula must be considered; often presents with herald bleed before massive hemorrhage
- Severe comorbidities — advanced age, cardiac disease, renal failure, or malignancy increase mortality risk
Systematic History: The “BLEEDS” Approach
Use the mnemonic “BLEEDS” to ensure comprehensive history taking for upper gastrointestinal bleeding:
- B — Bleeding characteristics: What does it look like? Hematemesis (fresh red or coffee-ground)? Melena? Hematochezia? Volume and frequency?
- L — Liver disease and comorbidities: Any history of cirrhosis, hepatitis, alcohol use, or known varices? Other significant medical conditions?
- E — Events preceding: What happened before the bleeding? Retching or vomiting (Mallory-Weiss)? Abdominal pain (ulcer)? Recent stress or illness?
- E — Eating and dyspepsia: History of peptic ulcer disease? Dyspepsia, heartburn, or epigastric pain? Relationship of symptoms to meals?
- D — Drugs and toxins: NSAIDs, aspirin, anticoagulants, antiplatelet agents, corticosteroids? Alcohol use? Caustic ingestion?
- S — Systemic symptoms and severity: Lightheadedness, syncope, chest pain, dyspnea? Weight loss, anorexia (malignancy)? How much blood lost?
Targeted Questions by Suspected Cause
| Suspected Cause | Key Features | Ask This Question |
|---|---|---|
| Peptic ulcer disease | Epigastric pain, relation to meals, history of Helicobacter pylori, NSAID use | “Do you have burning or gnawing pain in your upper abdomen? Does eating make it better or worse? Have you ever been told you have an ulcer or H. pylori infection?” |
| Esophageal varices | Known liver disease, alcohol history, prior variceal bleeding, jaundice, ascites | “Have you ever been told you have liver disease or cirrhosis? How much alcohol do you drink? Have you ever had bleeding from your stomach or esophagus before?” |
| Mallory-Weiss tear | Forceful retching or vomiting preceding hematemesis, often alcohol-related | “Did you have severe vomiting or retching before the blood appeared? Were you drinking alcohol before this happened?” |
| Erosive esophagitis | Heartburn, acid regurgitation, dysphagia, odynophagia | “Do you frequently have heartburn or acid coming up into your throat? Do you have difficulty or pain when swallowing?” |
| Gastric malignancy | Weight loss, early satiety, anorexia, dysphagia, family history | “Have you lost weight without trying? Do you feel full quickly after eating? Has anyone in your family had stomach cancer?” |
| Aortoenteric fistula | Prior aortic aneurysm repair, abdominal aortic surgery, herald bleed | “Have you ever had surgery on the main blood vessel in your abdomen—an aortic aneurysm repair or bypass? Did you have a smaller episode of bleeding before this one?” |
| Stress-related mucosal disease | Recent critical illness, ICU admission, major surgery, burns, head injury | “Have you been in the hospital recently for a serious illness or surgery? Have you been in an intensive care unit?” |
| Dieulafoy lesion | Recurrent episodes of brisk bleeding, often elderly, may be on anticoagulation | “Have you had episodes of sudden, heavy bleeding before that seemed to stop on their own? Have previous endoscopies found a cause?” |
Medication and Social History
Medications That Cause or Worsen Upper Gastrointestinal Bleeding
- Nonsteroidal anti-inflammatory drugs (NSAIDs) — inhibit protective prostaglandins; increase ulcer risk 3 to 5 fold; risk increases with dose and duration
- Aspirin — even low-dose (81 mg) increases bleeding risk; combined with NSAIDs dramatically increases risk
- Anticoagulants (warfarin, direct oral anticoagulants, heparin) — do not cause ulcers but increase bleeding severity and duration
- Antiplatelet agents (clopidogrel, prasugrel, ticagrelor) — impair platelet function; dual antiplatelet therapy significantly increases risk
- Corticosteroids — alone have modest ulcer risk; combined with NSAIDs substantially increases risk
- Selective serotonin reuptake inhibitors — impair platelet function; increase risk when combined with NSAIDs
- Bisphosphonates — can cause erosive esophagitis if not taken properly
- Potassium chloride supplements — can cause localized mucosal injury
Social and Lifestyle History
- Alcohol use: Quantify intake; chronic heavy use causes cirrhosis and varices; acute intoxication associated with Mallory-Weiss tears and erosive gastritis
- Smoking: Increases ulcer risk and impairs ulcer healing; associated with gastric malignancy
- Illicit drug use: Cocaine can cause mesenteric ischemia; intravenous drug use associated with hepatitis and cirrhosis
- Dietary factors: Caffeine and spicy foods do not cause ulcers but may worsen dyspepsia
- Stress and recent illness: Critical illness, major surgery, burns, and head trauma predispose to stress ulceration
- Family history: Gastric cancer, peptic ulcer disease, Helicobacter pylori infection in family members
Quantifying Blood Loss
| Patient Description | Estimated Volume | Clinical Interpretation |
|---|---|---|
| “A few streaks of blood” | Less than 50 mL | Minor bleeding; may be from oropharyngeal source or minor mucosal lesion |
| “A tablespoon or two” | 15 to 30 mL | Small volume; requires investigation but usually not hemodynamically significant |
| “Half a cup” or “coffee cup full” | 100 to 250 mL | Moderate bleeding; warrants hospitalization and urgent endoscopy |
| “A bowl full” or “filled the toilet” | 500 mL or more | Significant bleeding; expect hemodynamic compromise; urgent intervention needed |
| “Multiple episodes” or “couldn’t stop” | Variable, often large | Ongoing bleeding is more concerning than a single large episode that has stopped |
Clinical Pearl: Patients Often Underestimate or Overestimate Blood Loss
Patient estimates of blood volume are notoriously unreliable. Small amounts of blood in water or vomitus can appear much larger than actual volume. Conversely, blood swallowed during sleep may not be recognized until it appears as melena. Focus on objective measures: hemodynamic status, orthostatic changes, hemoglobin trends, and ongoing signs of bleeding are more reliable than patient estimates of volume.
4. Physical Examination
A systematic approach for Upper Gastrointestinal Bleeding
Systematic Framework: The physical examination in upper gastrointestinal bleeding serves two critical purposes: (1) assessing hemodynamic stability and severity of blood loss, and (2) identifying clues to the underlying etiology. Use a structured “ABC then Head-to-Toe” approach to ensure nothing is missed in this potentially life-threatening condition.
General Inspection
- Level of consciousness: Alert and oriented versus confused, agitated, or obtunded (suggests significant hypovolemia or hepatic encephalopathy)
- Appearance: Comfortable at rest versus distressed; diaphoretic; pale or ashen skin color
- Respiratory effort: Tachypnea may indicate compensation for metabolic acidosis from hypoperfusion
- Skin color: Pallor of conjunctivae, nail beds, and palmar creases suggests anemia; jaundice suggests liver disease
- Visible blood: Check for blood on clothing, in emesis basin, on bed linens; look in mouth for fresh blood
- Nutritional status: Cachexia may suggest malignancy; muscle wasting in chronic liver disease
Vital Signs
| Vital Sign | What to Look For | Clinical Significance |
|---|---|---|
| Heart Rate | Tachycardia (greater than 100 bpm); note that beta-blockers may blunt this response | Heart rate greater than 100 suggests at least 15% blood volume loss; greater than 120 suggests greater than 30% loss; absence of tachycardia does not exclude significant bleeding in patients on beta-blockers |
| Blood Pressure | Hypotension (systolic less than 90 mmHg); narrowed pulse pressure | Hypotension indicates at least 30% to 40% blood volume loss; narrowed pulse pressure (less than 25 mmHg) is an early sign of compensation |
| Orthostatic Changes | Systolic drop greater than 20 mmHg or heart rate increase greater than 20 bpm on standing | Positive orthostatic changes suggest 15% to 20% blood volume loss; perform only if patient is stable enough to stand safely |
| Respiratory Rate | Tachypnea (greater than 20 breaths per minute) | May indicate compensation for metabolic acidosis from tissue hypoperfusion; also consider aspiration if altered consciousness |
| Temperature | Fever or hypothermia | Fever may indicate infection (spontaneous bacterial peritonitis in cirrhotics) or perforation; hypothermia suggests severe shock |
| Oxygen Saturation | Hypoxemia (less than 94% on room air) | May indicate aspiration, pulmonary edema from over-resuscitation, or underlying cardiopulmonary disease |
Shock Index: A Useful Bedside Tool
The Shock Index (heart rate divided by systolic blood pressure) is a simple, rapid assessment of hemodynamic status. A normal shock index is 0.5 to 0.7. A shock index greater than 1.0 (heart rate exceeds systolic blood pressure) indicates significant hemorrhage and predicts need for transfusion, intervention, and increased mortality. Example: Heart rate 110, blood pressure 100/70 gives a shock index of 1.1, indicating significant blood loss even though individual vital signs may appear only mildly abnormal.
Head and Neck Examination
Eyes
- Conjunctival pallor: Suggests anemia; compare to inner lower eyelid
- Scleral icterus: Jaundice visible when bilirubin greater than 2.5 mg/dL; suggests liver disease
- Kayser-Fleischer rings: Brown-green rings at corneal limbus; Wilson disease (rare cause of cirrhosis)
Oral Cavity
- Fresh blood: May indicate active hematemesis or swallowed blood from nasopharyngeal source
- Fetor hepaticus: Sweet, musty breath odor in hepatic encephalopathy
- Dental erosions: May suggest chronic vomiting or acid reflux
- Mucosal pallor: Pale oral mucosa and tongue suggest anemia
Neck
- Jugular venous pressure: Low JVP suggests hypovolemia; elevated JVP may indicate cardiac disease or fluid overload from aggressive resuscitation
- Lymphadenopathy: Left supraclavicular node (Virchow node) may indicate gastric malignancy
Cardiovascular Examination
- Capillary refill: Delayed refill (greater than 2 seconds) indicates peripheral vasoconstriction from hypovolemia
- Peripheral pulses: Weak, thready pulses suggest significant blood loss; compare central to peripheral pulses
- Heart sounds: Flow murmur may develop with severe anemia; assess for underlying valvular disease
- Signs of heart failure: May indicate cardiac comorbidity that limits tolerance of blood loss and resuscitation
Abdominal Examination
Inspection
- Distension: May indicate ascites (cirrhosis) or bowel obstruction
- Caput medusae: Dilated periumbilical veins radiating from umbilicus; portal hypertension
- Surgical scars: Prior abdominal aortic surgery (aortoenteric fistula); prior gastric surgery (stomal ulcers)
- Spider angiomata: Small, red, spider-like vascular lesions on upper trunk; chronic liver disease
Palpation
- Tenderness: Epigastric tenderness suggests peptic ulcer disease or gastritis; diffuse tenderness with guarding may indicate perforation
- Hepatomegaly: Enlarged, firm, nodular liver suggests cirrhosis or malignancy
- Splenomegaly: Enlarged spleen suggests portal hypertension
- Masses: Epigastric mass may indicate gastric malignancy; pulsatile mass suggests aortic aneurysm
- Ascites: Shifting dullness and fluid wave indicate significant ascites; suggests portal hypertension
Auscultation
- Bowel sounds: Hyperactive bowel sounds are common with blood in the gastrointestinal tract (blood is cathartic)
- Bruits: Hepatic bruit may indicate hepatocellular carcinoma; abdominal bruit may indicate aneurysm
Rectal Examination
Essential Component of the Evaluation
Rectal examination should be performed in all patients with suspected gastrointestinal bleeding to assess stool character:
- Melena: Black, tarry, sticky stool with characteristic foul odor; indicates upper gastrointestinal bleeding (blood in gut for at least 8 hours)
- Hematochezia: Bright red or maroon blood; usually lower gastrointestinal source but can occur with massive upper gastrointestinal bleeding
- Occult blood: Stool may appear normal but test positive for blood
- Masses: Rectal masses may indicate malignancy; hemorrhoids are common but do not cause melena
Stigmata of Chronic Liver Disease
The presence of signs of chronic liver disease should raise suspicion for variceal bleeding, which requires specific management:
| Finding | Location | Significance |
|---|---|---|
| Jaundice | Sclera, skin, mucous membranes | Indicates impaired bilirubin metabolism; severity correlates with liver dysfunction |
| Spider angiomata | Face, neck, upper chest, arms | Central arteriole with radiating vessels; more than 5 strongly suggests cirrhosis |
| Palmar erythema | Thenar and hypothenar eminences | Reddening of palms; due to altered estrogen metabolism |
| Gynecomastia | Breast tissue in males | Due to altered estrogen-androgen balance in cirrhosis |
| Testicular atrophy | Testes | Due to altered hormone metabolism and direct toxic effect of alcohol |
| Ascites | Abdomen | Indicates portal hypertension and hypoalbuminemia; associated with varices |
| Caput medusae | Periumbilical region | Dilated abdominal wall veins; indicates portal hypertension with collateral formation |
| Asterixis | Hands (when wrists extended) | Flapping tremor; indicates hepatic encephalopathy |
| Dupuytren contracture | Palmar fascia of hands | Thickening and contracture; associated with alcohol use |
| Terry nails | Fingernails | White nail beds with normal distal pink band; associated with cirrhosis |
Expected Findings by Etiology
| Condition | General Appearance | Abdominal Findings | Other Clues |
|---|---|---|---|
| Peptic ulcer disease | May appear well if bleeding mild; pallor and tachycardia if significant | Epigastric tenderness; peritonitis if perforated | Often unremarkable; history more revealing than examination |
| Variceal bleeding | Jaundice, muscle wasting, encephalopathy may be present | Ascites, splenomegaly, caput medusae, hepatomegaly | Multiple stigmata of chronic liver disease; may have prior scars from transjugular intrahepatic portosystemic shunt or transplant evaluation |
| Mallory-Weiss tear | May appear intoxicated; signs of recent vomiting | Usually non-tender; no peritonitis | History of retching preceding hematemesis is key |
| Gastric malignancy | Cachexia, weight loss, pallor from chronic blood loss | Epigastric mass, hepatomegaly (metastases), ascites | Virchow node (left supraclavicular); Sister Mary Joseph nodule (periumbilical) |
| Aortoenteric fistula | May be deceptively stable between episodes; then sudden collapse | Prior surgical scar; pulsatile mass (if not previously repaired) | History of aortic surgery is critical; herald bleed precedes exsanguination |
| Erosive gastritis | Often critically ill from other cause; ICU patient | Findings related to underlying critical illness | Context of recent surgery, burns, head injury, sepsis |
Important Teaching Point
Physical examination may be remarkably normal in upper gastrointestinal bleeding. Many patients with peptic ulcer disease, Mallory-Weiss tears, or even significant bleeding have unremarkable abdominal examinations. The absence of tenderness, masses, or organomegaly does not exclude serious pathology. Hemodynamic assessment is often more informative than the abdominal examination. Always trust concerning vital signs over a reassuring abdominal examination.
5. Differential Diagnosis
Systematic approach organized by probability and clinical features
The differential diagnosis of upper gastrointestinal bleeding is broad, but a probability-based approach helps prioritize the evaluation. The “Big Four” causes—peptic ulcer disease, erosive disease, varices, and Mallory-Weiss tears—account for approximately 80% to 90% of cases. However, it is essential to consider less common but serious causes, particularly in patients with atypical presentations or risk factors.
Non-Variceal Upper Gastrointestinal Bleeding (80% to 90% of cases)
| Probability | Condition | Key Features | Red Flags |
|---|---|---|---|
| COMMON (50% to 70%) | Peptic ulcer disease (gastric and duodenal ulcers) | Epigastric pain, NSAID or aspirin use, history of Helicobacter pylori, prior ulcer disease; duodenal ulcers may have pain relieved by eating | Sudden severe pain (perforation); rigid abdomen; hemodynamic instability with large visible vessel |
| COMMON (15% to 25%) | Erosive gastritis, esophagitis, or duodenitis | NSAID use, alcohol, stress (ICU patients), heartburn, dyspepsia; usually multiple superficial lesions rather than single deep ulcer | Massive bleeding is uncommon; if severe, consider other diagnoses |
| COMMON (5% to 15%) | Mallory-Weiss tear | Forceful retching or vomiting preceding hematemesis; often alcohol-related; typically self-limited | Boerhaave syndrome (esophageal perforation) if severe chest pain, subcutaneous emphysema |
| LESS COMMON (2% to 5%) | Upper gastrointestinal malignancy (gastric, esophageal) | Weight loss, anorexia, early satiety, dysphagia; older age; family history; chronic bleeding more common than acute hemorrhage | Virchow node; Sister Mary Joseph nodule; hepatomegaly; ascites (metastatic disease) |
| LESS COMMON (1% to 2%) | Dieulafoy lesion | Recurrent episodes of brisk arterial bleeding; often elderly; minimal surrounding mucosal abnormality; commonly in proximal stomach | Massive hemorrhage; difficult to identify endoscopically when not actively bleeding |
| LESS COMMON (1% to 2%) | Angiodysplasia (vascular ectasia) | Elderly patients; associated with aortic stenosis and chronic kidney disease; often chronic occult blood loss rather than overt bleeding | Recurrent bleeding despite treatment; may have lesions throughout gastrointestinal tract |
| UNCOMMON BUT SERIOUS (less than 1%) | Aortoenteric fistula | Prior aortic aneurysm repair or aortic surgery; herald bleed followed by massive hemorrhage; abdominal or back pain | Exsanguinating hemorrhage; must be considered in any patient with prior aortic surgery |
| UNCOMMON BUT SERIOUS (less than 1%) | Hemobilia (bleeding into biliary tree) | Recent liver biopsy, hepatobiliary surgery, or trauma; right upper quadrant pain, jaundice, gastrointestinal bleeding (Quincke triad) | May present days to weeks after hepatobiliary procedure |
| UNCOMMON BUT SERIOUS (less than 1%) | Hemosuccus pancreaticus (bleeding into pancreatic duct) | History of chronic pancreatitis or pancreatic pseudoaneurysm; intermittent bleeding with abdominal pain | Often missed on initial endoscopy; requires CT angiography or angiography for diagnosis |
Variceal Upper Gastrointestinal Bleeding (10% to 20% of cases)
Key Point: Variceal bleeding should be suspected in any patient with known or suspected liver disease, portal hypertension, or stigmata of chronic liver disease. Variceal bleeding carries significantly higher mortality (15% to 30%) and requires specific management distinct from non-variceal bleeding.
| Type | Frequency Among Variceal Bleeds | Key Features | Management Considerations |
|---|---|---|---|
| Esophageal varices | 70% to 80% | Located in distal esophagus; graded by size (small, medium, large) and presence of red wale marks; rupture risk increases with size and portal pressure | Band ligation is first-line endoscopic therapy; vasoactive drugs (octreotide); TIPS for refractory bleeding |
| Gastric varices | 20% to 30% | Located in gastric fundus or cardia; classified by location (gastroesophageal varices type 1 and 2, isolated gastric varices type 1 and 2); more difficult to treat than esophageal varices | Cyanoacrylate glue injection preferred over banding; TIPS often needed; higher rebleeding rate than esophageal varices |
| Portal hypertensive gastropathy | 5% to 10% | Mosaic or snakeskin pattern of gastric mucosa; typically causes chronic blood loss rather than acute hemorrhage; associated with portal hypertension | Beta-blockers reduce portal pressure; iron supplementation; TIPS for severe cases |
| Gastric antral vascular ectasia (watermelon stomach) | Less than 5% | Linear red streaks radiating from pylorus (watermelon stripe pattern); associated with cirrhosis and systemic sclerosis; chronic blood loss | Argon plasma coagulation; multiple sessions often required; does not respond to portal pressure reduction |
Anatomical Approach to Differential Diagnosis
Esophagus
Esophageal varices
Erosive esophagitis
Mallory-Weiss tear
Esophageal ulcer
Esophageal malignancy
Boerhaave syndrome (rare)
Stomach
Gastric ulcer
Erosive gastritis
Gastric varices
Gastric malignancy
Dieulafoy lesion
Gastric antral vascular ectasia
Portal hypertensive gastropathy
Duodenum
Duodenal ulcer (most common cause overall)
Erosive duodenitis
Aortoenteric fistula
Duodenal malignancy (rare)
Hemobilia (ampulla of Vater)
Hemosuccus pancreaticus
Extra-Luminal Sources
Aortoenteric fistula
Hemobilia
Hemosuccus pancreaticus
Nasopharyngeal bleeding (swallowed blood)
Pulmonary bleeding (hemoptysis vs hematemesis)
Drug-Induced Upper Gastrointestinal Bleeding
| Drug or Drug Class | Mechanism | Characteristics | Risk Reduction Strategy |
|---|---|---|---|
| Nonsteroidal anti-inflammatory drugs (NSAIDs) | Inhibition of cyclooxygenase-1 reduces protective prostaglandins; direct topical injury to mucosa | 3 to 5 fold increased ulcer risk; gastric ulcers more common than duodenal; risk increases with dose, duration, and age | Use lowest effective dose for shortest duration; co-prescribe proton pump inhibitor; consider COX-2 selective agents |
| Aspirin (including low-dose) | Irreversible COX-1 inhibition; impaired platelet function persists for platelet lifespan (7 to 10 days) | Even 81 mg daily increases risk; combined with NSAIDs dramatically increases risk; enteric coating does not reduce risk | Co-prescribe proton pump inhibitor in high-risk patients; avoid concurrent NSAIDs; Helicobacter pylori eradication |
| Warfarin | Does not cause ulcers but increases severity and duration of bleeding from any source | Supratherapeutic INR greatly increases risk; bleeding often unmasks occult lesions | Maintain INR in therapeutic range; reversal with vitamin K, prothrombin complex concentrate, or fresh frozen plasma |
| Direct oral anticoagulants (dabigatran, rivaroxaban, apixaban, edoxaban) | Direct thrombin or factor Xa inhibition; dabigatran may have direct mucosal effect | Dabigatran associated with higher gastrointestinal bleeding risk than warfarin; rivaroxaban intermediate; apixaban lowest risk | Specific reversal agents available (idarucizumab for dabigatran; andexanet alfa for factor Xa inhibitors); prothrombin complex concentrate |
| Clopidogrel and other P2Y12 inhibitors | Irreversible platelet inhibition; impairs primary hemostasis | Increased bleeding risk; combined with aspirin (dual antiplatelet therapy) significantly increases risk | Proton pump inhibitor co-prescription (some interaction with clopidogrel but benefit outweighs risk); platelet transfusion if severe bleeding |
| Corticosteroids | Impair mucosal healing; reduce mucus production; modest ulcer risk alone | Risk greatly increased when combined with NSAIDs; higher with high doses and prolonged use | Avoid concurrent NSAIDs; consider proton pump inhibitor prophylaxis in high-risk patients |
| Selective serotonin reuptake inhibitors (SSRIs) | Deplete platelet serotonin, impairing platelet aggregation | Modest increased risk; significantly increased when combined with NSAIDs or anticoagulants | Consider proton pump inhibitor if also on NSAIDs or anticoagulants |
| Bisphosphonates (oral) | Direct mucosal irritation if pill lodges in esophagus | Erosive esophagitis, esophageal ulcers; proper administration technique critical | Take with full glass of water; remain upright for 30 minutes; consider intravenous formulations if esophageal symptoms |
Quick Reference: “If You See This, Think This”
| Clinical Clue | Think This First | Next Step |
|---|---|---|
| NSAID or aspirin use with epigastric pain | Peptic ulcer disease | Stop NSAIDs; high-dose proton pump inhibitor; urgent endoscopy |
| Known cirrhosis or stigmata of liver disease | Variceal bleeding | Vasoactive drugs (octreotide); antibiotics; urgent endoscopy with band ligation |
| Forceful retching before hematemesis | Mallory-Weiss tear | Usually self-limited; endoscopy to confirm; treat if active bleeding |
| Prior aortic surgery with gastrointestinal bleeding | Aortoenteric fistula | CT angiography; surgical emergency; do not delay for endoscopy if high suspicion |
| Weight loss, dysphagia, early satiety | Upper gastrointestinal malignancy | Urgent endoscopy with biopsy; staging CT if malignancy confirmed |
| Recent liver biopsy or hepatobiliary procedure | Hemobilia | CT angiography or hepatic angiography; endoscopy may show blood at ampulla |
| Chronic pancreatitis with intermittent bleeding | Hemosuccus pancreaticus | CT angiography; angiographic embolization if pseudoaneurysm identified |
| ICU patient with stress, burns, or head injury | Stress-related mucosal disease | Proton pump inhibitor therapy; address underlying critical illness |
| Elderly with recurrent brisk bleeding, negative endoscopy | Dieulafoy lesion or angiodysplasia | Repeat endoscopy during active bleeding; consider capsule endoscopy or angiography |
| Aortic stenosis with chronic anemia | Angiodysplasia (Heyde syndrome) | Endoscopy; treat angiodysplasia; consider aortic valve replacement for definitive treatment |
6. Diagnostic Investigations
A stepwise, clinically-guided approach to the evaluation of Upper Gastrointestinal Bleeding
The investigation of upper gastrointestinal bleeding serves three purposes: (1) assessing severity and guiding resuscitation, (2) identifying the bleeding source and etiology, and (3) risk stratification for prognosis and disposition. Initial laboratory tests should be obtained promptly in all patients, while advanced investigations are guided by clinical presentation and suspected etiology.
Baseline Investigations for All Patients
| Investigation | Purpose | What to Look For | Practical Points |
|---|---|---|---|
| Complete blood count | Assess severity of blood loss; baseline hemoglobin for transfusion decisions | Hemoglobin and hematocrit (may be normal initially); platelet count (thrombocytopenia in liver disease); MCV (microcytic anemia suggests chronic blood loss) | Initial hemoglobin may underestimate blood loss; repeat in 6 to 8 hours; hemoglobin less than 7 g/dL generally indicates need for transfusion |
| Blood type and crossmatch | Prepare for potential transfusion | ABO and Rh type; antibody screen | Type and screen for stable patients; type and crossmatch 2 to 4 units for active bleeding or hemodynamic instability |
| Coagulation studies (PT/INR, aPTT) | Assess coagulation status; guide reversal of anticoagulation | Elevated INR (warfarin, liver disease); prolonged aPTT (heparin, intrinsic pathway defects) | INR greater than 1.5 may require correction before endoscopy; liver disease causes complex coagulopathy not reflected by INR alone |
| Basic metabolic panel | Assess renal function; guide fluid resuscitation; calculate risk scores | Elevated BUN (blood in gut increases urea absorption); BUN:creatinine ratio greater than 30:1 suggests upper gastrointestinal source; electrolyte abnormalities | Prerenal azotemia common; BUN used in Glasgow-Blatchford score; correct electrolytes before endoscopy |
| Liver function tests | Identify liver disease; assess synthetic function | Elevated bilirubin (jaundice); low albumin (poor synthetic function); elevated transaminases (hepatocellular injury) | Low albumin (less than 3.0 g/dL) is component of AIMS65 score; liver disease suggests variceal bleeding |
| Lactate | Assess tissue perfusion; marker of shock severity | Elevated lactate (greater than 2 mmol/L) indicates tissue hypoperfusion | Serial lactate measurements guide adequacy of resuscitation; persistent elevation indicates ongoing shock |
| Electrocardiogram | Detect cardiac ischemia from anemia; assess for arrhythmias | ST changes, T-wave inversions (demand ischemia); atrial fibrillation (may affect anticoagulation decisions) | Type 2 myocardial infarction can occur from severe anemia; higher transfusion threshold if cardiac ischemia present |
BUN:Creatinine Ratio in Upper Gastrointestinal Bleeding
An elevated BUN:creatinine ratio (greater than 30:1) is a useful clue suggesting upper gastrointestinal bleeding. Blood in the gastrointestinal tract is digested, and the protein load increases urea absorption in the small intestine. This elevates BUN disproportionately to creatinine. However, this finding is not specific—hypovolemia, high protein intake, and catabolic states can also elevate the ratio. A normal ratio does not exclude upper gastrointestinal bleeding.
Risk Stratification Scoring Systems
Glasgow-Blatchford Score (Pre-Endoscopy)
Purpose: Identifies low-risk patients who may not require hospital admission or urgent intervention
Components:
- Blood urea nitrogen (BUN)
- Hemoglobin (sex-specific)
- Systolic blood pressure
- Heart rate
- Melena
- Syncope
- Hepatic disease
- Cardiac failure
Interpretation: Score of 0 to 1 identifies very low-risk patients (less than 1% chance of needing intervention); may be candidates for outpatient endoscopy
AIMS65 Score
Purpose: Predicts in-hospital mortality; simple bedside calculation
Components (1 point each):
- Albumin less than 3.0 g/dL
- INR greater than 1.5
- Mental status altered
- Systolic blood pressure less than or equal to 90 mmHg
- Age greater than 65 years
Interpretation: Score 0 = 0.3% mortality; Score 2 = 5% mortality; Score 5 = 25% mortality
Upper Endoscopy (Esophagogastroduodenoscopy)
Endoscopy is the cornerstone of diagnosis and treatment in upper gastrointestinal bleeding. It identifies the bleeding source in 90% to 95% of cases and allows therapeutic intervention. Timing depends on clinical presentation and risk stratification.
| Timing Category | Timeframe | Indications | Rationale |
|---|---|---|---|
| Emergent | Within 12 hours | Hemodynamic instability despite resuscitation; suspected variceal bleeding; ongoing active bleeding | Earlier endoscopy allows therapeutic intervention; delay increases mortality in high-risk patients |
| Urgent | Within 24 hours | Most patients hospitalized with upper gastrointestinal bleeding; hemodynamically stable after resuscitation | Identifies source; allows risk stratification based on endoscopic findings; enables early discharge if low-risk features |
| Elective | Within 72 hours or outpatient | Very low-risk patients (Glasgow-Blatchford 0 to 1); stable with minor bleeding; reliable follow-up | Avoids unnecessary hospitalization; similar outcomes to urgent endoscopy in carefully selected low-risk patients |
Endoscopic Findings and Risk Stratification (Forrest Classification for Ulcers)
| Forrest Class | Description | Rebleeding Risk | Management |
|---|---|---|---|
| Ia | Spurting arterial hemorrhage | 90% | Endoscopic therapy required; ICU admission |
| Ib | Oozing hemorrhage | 50% | Endoscopic therapy required; ICU admission |
| IIa | Non-bleeding visible vessel | 40% to 50% | Endoscopic therapy required; high-dose proton pump inhibitor |
| IIb | Adherent clot | 20% to 30% | Consider endoscopic therapy after clot removal; high-dose proton pump inhibitor |
| IIc | Flat pigmented spot | 10% | No endoscopic therapy needed; oral proton pump inhibitor; consider early discharge |
| III | Clean-based ulcer | Less than 5% | No endoscopic therapy needed; oral proton pump inhibitor; early discharge possible |
Targeted Investigations by Suspected Etiology
If Suspecting Variceal Bleeding
First-Line Tests
- Liver function tests: Assess severity of liver disease; elevated bilirubin, low albumin, prolonged INR indicate decompensation
- Complete blood count: Thrombocytopenia (platelet count less than 150,000) suggests portal hypertension with hypersplenism
- Coagulation studies: Prolonged PT/INR reflects impaired hepatic synthetic function
Additional Investigations
- Abdominal ultrasound with Doppler: Assess liver morphology, portal vein patency, splenomegaly, ascites
- Paracentesis: If ascites present, rule out spontaneous bacterial peritonitis (cell count, culture); SBP common precipitant of variceal bleeding
- Hepatitis serologies: Hepatitis B and C if liver disease etiology unknown
If Suspecting Peptic Ulcer Disease
First-Line Tests
- Helicobacter pylori testing: Stool antigen or urea breath test (if not on proton pump inhibitor); biopsy-based testing at endoscopy (rapid urease test, histology)
- Medication review: Document NSAID, aspirin, anticoagulant, and antiplatelet use
Additional Investigations
- Fasting gastrin level: If recurrent ulcers, ulcers in unusual locations, or multiple ulcers; consider Zollinger-Ellison syndrome (gastrinoma)
- Ulcer biopsy: Gastric ulcers should be biopsied to exclude malignancy; duodenal ulcers rarely malignant
If Suspecting Aortoenteric Fistula
Do Not Delay Imaging for Endoscopy
If aortoenteric fistula is suspected (prior aortic surgery, herald bleed, abdominal pain), CT angiography should be performed urgently. Findings include: perigraft fluid or gas, loss of fat plane between graft and duodenum, pseudoaneurysm, or extravasation of contrast. Endoscopy may show erosion of graft into duodenum but can be falsely negative. This is a surgical emergency with high mortality if not promptly recognized.
If Endoscopy is Non-Diagnostic
| Situation | Next Investigation | Rationale |
|---|---|---|
| Ongoing bleeding, no source identified | Repeat endoscopy; CT angiography; tagged red blood cell scan | Lesions may be missed due to blood obscuring view; angiography can detect and treat active bleeding (greater than 0.5 mL/min for CT, greater than 0.1 mL/min for catheter angiography) |
| Recurrent bleeding after initial negative workup | Repeat endoscopy during active bleeding; video capsule endoscopy; push enteroscopy | Dieulafoy lesions and angiodysplasia may only be visible during active bleeding; small bowel source may have been missed |
| Obscure gastrointestinal bleeding (recurrent, source unclear) | Video capsule endoscopy; deep enteroscopy (balloon-assisted); CT enterography | Evaluates small bowel beyond reach of standard endoscopy; identifies angiodysplasia, small bowel tumors, Crohn disease |
| Suspected vascular abnormality | CT angiography; catheter angiography with possible embolization | Identifies Dieulafoy lesions, pseudoaneurysms, arteriovenous malformations; allows therapeutic embolization |
Proton Pump Inhibitor Therapy
Proton Pump Inhibitor Dosing in Upper Gastrointestinal Bleeding
High-dose proton pump inhibitor therapy is a cornerstone of management for non-variceal upper gastrointestinal bleeding. The goal is to maintain gastric pH greater than 6, which optimizes clot stability.
- High-risk endoscopic findings (Forrest Ia, Ib, IIa, IIb): Intravenous proton pump inhibitor bolus (80 mg) followed by continuous infusion (8 mg/hour) for 72 hours, then oral therapy
- Low-risk endoscopic findings (Forrest IIc, III): Oral proton pump inhibitor (e.g., omeprazole 40 mg twice daily) is sufficient
- Pre-endoscopy: Intravenous proton pump inhibitor can be started empirically but does not replace urgent endoscopy; may downstage lesions and reduce need for endoscopic therapy
7. Pattern Recognition and Clinical Decision-Making
Practical algorithms and decision pathways
Step 1: Is This Urgent?
| Clinical Scenario | Urgency Level | Immediate Action |
|---|---|---|
| Hemodynamic instability (systolic blood pressure less than 90 mmHg, heart rate greater than 120 bpm, altered mental status) | EMERGENT | Two large-bore IV lines; crystalloid resuscitation; type and crossmatch 4 to 6 units; activate massive transfusion protocol if needed; ICU admission; emergent endoscopy within 12 hours |
| Known or suspected variceal bleeding (cirrhosis, stigmata of liver disease) | EMERGENT | IV access; start octreotide 50 mcg bolus then 50 mcg/hour infusion; IV antibiotics (ceftriaxone 1g); urgent endoscopy within 12 hours; consider ICU admission |
| Prior aortic surgery with gastrointestinal bleeding (any amount) | EMERGENT | CT angiography immediately; vascular surgery consultation; prepare for emergent surgery; do not assume negative endoscopy excludes aortoenteric fistula |
| Active hematemesis or hematochezia with hemodynamic stability | URGENT | Hospital admission; IV proton pump inhibitor; NPO; type and screen; endoscopy within 24 hours; monitor for hemodynamic changes |
| Melena with stable vital signs, no significant comorbidities | URGENT | Hospital admission; IV proton pump inhibitor; calculate Glasgow-Blatchford score; endoscopy within 24 hours |
| Coffee-ground emesis, single episode, hemodynamically stable, Glasgow-Blatchford 0 to 1 | LOW RISK | May consider outpatient endoscopy within 72 hours in carefully selected patients with reliable follow-up; oral proton pump inhibitor; return precautions |
| Positive fecal occult blood, asymptomatic, stable hemoglobin | ROUTINE | Outpatient evaluation; consider upper endoscopy and colonoscopy; iron studies; oral proton pump inhibitor trial if dyspepsia present |
Step 2: Initial Resuscitation and Stabilization
The “ABC-VOM” Approach to Initial Management:
- Airway — Protect airway if altered mental status, massive hematemesis, or high aspiration risk; consider intubation before endoscopy in obtunded patients
- Breathing — Supplemental oxygen; monitor for aspiration
- Circulation — Two large-bore IV catheters (16 to 18 gauge); crystalloid resuscitation; blood products as needed
- Vascular access and Volume — Central line if difficult access or need for vasopressors; goal-directed resuscitation
- Organ support — ICU admission for hemodynamic instability; monitor urine output; lactate clearance
- Medications — IV proton pump inhibitor; octreotide and antibiotics if variceal bleeding suspected; hold anticoagulants
Step 3: Transfusion Decision-Making
| Clinical Situation | Transfusion Threshold | Rationale |
|---|---|---|
| Hemodynamically stable, no cardiac disease | Hemoglobin less than 7 g/dL | Restrictive transfusion strategy associated with lower mortality and rebleeding in upper gastrointestinal bleeding |
| Active coronary artery disease or acute coronary syndrome | Hemoglobin less than 8 to 9 g/dL | Higher threshold to maintain oxygen delivery to myocardium; type 2 myocardial infarction risk |
| Hemodynamic instability, ongoing hemorrhage | Transfuse empirically; do not wait for hemoglobin | Initial hemoglobin may be falsely normal; clinical status takes priority over laboratory values |
| Variceal bleeding | Hemoglobin target 7 to 8 g/dL; avoid over-transfusion | Over-transfusion increases portal pressure and rebleeding risk in cirrhotics |
| Coagulopathy (INR greater than 1.5 to 2.0) | Consider fresh frozen plasma or prothrombin complex concentrate | Correct coagulopathy to allow endoscopic intervention and reduce bleeding; target INR less than 2.5 |
| Thrombocytopenia (platelets less than 50,000/μL) | Platelet transfusion before endoscopy or with active bleeding | Adequate platelet count needed for hemostasis; target greater than 50,000/μL |
Avoid Over-Transfusion in Variceal Bleeding
In patients with cirrhosis and variceal bleeding, a restrictive transfusion strategy (target hemoglobin 7 to 8 g/dL) is associated with improved survival compared to liberal transfusion. Over-transfusion increases portal venous pressure and may precipitate rebleeding. Avoid hemoglobin targets above 9 g/dL unless there is ongoing massive hemorrhage or significant cardiac comorbidity.
Step 4: Variceal vs Non-Variceal Pathway
Non-Variceal Bleeding Pathway
- IV proton pump inhibitor (80 mg bolus, then 8 mg/hour infusion or intermittent dosing)
- Risk stratification (Glasgow-Blatchford, AIMS65)
- Endoscopy within 24 hours (within 12 hours if high-risk)
- Endoscopic therapy for high-risk lesions (Forrest Ia, Ib, IIa, IIb)
- Continue high-dose IV proton pump inhibitor for 72 hours if high-risk stigmata
- Test and treat Helicobacter pylori
- Review and modify medications (stop NSAIDs, manage anticoagulation)
Variceal Bleeding Pathway
- Vasoactive drug: Octreotide 50 mcg bolus, then 50 mcg/hour for 3 to 5 days (or terlipressin where available)
- Prophylactic antibiotics: Ceftriaxone 1 g IV daily for 7 days (reduces mortality)
- Emergent endoscopy within 12 hours with band ligation (esophageal varices) or cyanoacrylate injection (gastric varices)
- If uncontrolled bleeding: Balloon tamponade as bridge; consider early TIPS (within 72 hours in high-risk patients)
- Secondary prophylaxis: Non-selective beta-blocker plus repeat band ligation
- Address underlying liver disease; evaluate for transplantation if appropriate
“What Do I Do If…” Decision Reference
| Clinical Situation | Immediate Action | Next Step |
|---|---|---|
| Patient on warfarin with INR 4.5 and active bleeding | Hold warfarin; give IV vitamin K 10 mg; 4-factor prothrombin complex concentrate (25 to 50 units/kg) for rapid reversal | Recheck INR in 6 hours; proceed to endoscopy when INR less than 2.5; reassess need for anticoagulation after stabilization |
| Patient on dabigatran with serious bleeding | Hold dabigatran; give idarucizumab 5 g IV (specific reversal agent) | Proceed to endoscopy; idarucizumab provides immediate reversal; reassess anticoagulation indication |
| Patient on rivaroxaban or apixaban with serious bleeding | Hold anticoagulant; andexanet alfa if available (400 to 800 mg bolus, then infusion); otherwise 4-factor prothrombin complex concentrate | Proceed to endoscopy; drug levels may help guide management; short half-life means effect wanes in 12 to 24 hours |
| Patient on dual antiplatelet therapy (aspirin plus clopidogrel) after recent coronary stent | Continue aspirin if possible; hold P2Y12 inhibitor; discuss with cardiology urgently | Endoscopy with hemostasis; balance bleeding risk versus stent thrombosis risk; restart antiplatelet therapy as soon as hemostasis achieved |
| Rebleeding after initial endoscopic therapy | Assess hemodynamic status; resuscitate; repeat endoscopy | Second endoscopic therapy attempt; if fails, consider interventional radiology (embolization) or surgery |
| Massive hemorrhage unresponsive to resuscitation | Activate massive transfusion protocol (1:1:1 ratio of packed red blood cells, fresh frozen plasma, platelets); consider intubation for airway protection | Emergent endoscopy or interventional radiology; surgery for uncontrolled bleeding; if variceal, emergent TIPS |
| Endoscopy shows clean-based ulcer (Forrest III) | No endoscopic therapy needed; switch to oral proton pump inhibitor | Can discharge within 24 hours if stable; outpatient Helicobacter pylori testing; follow-up for ulcer healing |
| Endoscopy non-diagnostic but ongoing bleeding suspected | Repeat endoscopy; consider CT angiography if hemodynamically significant | If still non-diagnostic: tagged red blood cell scan, capsule endoscopy, or angiography with embolization |
| Suspected aortoenteric fistula with herald bleed, now stable | CT angiography immediately; vascular surgery consultation | Even if CT negative, maintain high suspicion; may need operative exploration; do not discharge without definitive evaluation |
Troubleshooting Refractory Upper Gastrointestinal Bleeding
Ask These Questions When Bleeding Persists
- Was the bleeding source correctly identified? Consider repeat endoscopy, CT angiography, or evaluation for missed lesions (Dieulafoy, small bowel source)
- Was endoscopic therapy adequate? Combination therapy (injection plus thermal or mechanical) is more effective than monotherapy for high-risk ulcers
- Is there ongoing coagulopathy? Correct INR, platelet count; consider factor replacement; assess for disseminated intravascular coagulation in critically ill patients
- Are medications contributing? Ensure anticoagulants and antiplatelets are appropriately held; confirm adequate proton pump inhibitor dosing
- Is this variceal bleeding being treated appropriately? Vasoactive drugs, antibiotics, and band ligation should all be employed; consider TIPS for refractory variceal bleeding
- Should interventional radiology or surgery be involved? Angiographic embolization for failed endoscopic therapy; surgery for refractory bleeding, perforation, or aortoenteric fistula
8. Clinical Pearls and Pitfalls
Practical wisdom — learn from successes and avoid common mistakes
Must-Know Clinical Pearls
Initial hemoglobin is misleading: In acute hemorrhage, hemoglobin may be normal initially because plasma and red cells are lost proportionally. Clinical assessment of hemodynamic status is more reliable than the initial hemoglobin. Repeat hemoglobin in 6 to 8 hours to assess true blood loss.
The Shock Index is your friend: Heart rate divided by systolic blood pressure greater than 1.0 indicates significant hemorrhage and predicts need for intervention, even when individual vital signs appear only mildly abnormal. Calculate it on every patient.
Melena requires only 50 to 100 mL of blood: A small amount of blood in the upper gastrointestinal tract produces impressive-looking melena. Melena alone does not indicate massive hemorrhage, but it does confirm upper gastrointestinal source in most cases.
Hematochezia from an upper source means massive bleeding: If a patient has bright red blood per rectum and an upper gastrointestinal source is confirmed, this indicates rapid hemorrhage (typically greater than 1000 mL) with fast intestinal transit. These patients are critically ill.
Restrictive transfusion saves lives: In stable patients with upper gastrointestinal bleeding, transfusing to a target hemoglobin of 7 g/dL (rather than 9 g/dL) reduces mortality and rebleeding. This is especially important in variceal bleeding where over-transfusion increases portal pressure.
Antibiotics reduce mortality in variceal bleeding: Prophylactic antibiotics (ceftriaxone 1 g daily) in patients with cirrhosis and gastrointestinal bleeding reduce infections and mortality. Give antibiotics even before endoscopy confirms varices if liver disease is suspected.
Glasgow-Blatchford score of 0 to 1 identifies safe discharges: Patients with Glasgow-Blatchford score of 0 to 1 have less than 1% chance of needing intervention and can often be managed with outpatient endoscopy. This prevents unnecessary hospitalizations.
Always ask about prior aortic surgery: Aortoenteric fistula is rare but catastrophic. A herald bleed (sentinel bleed) often precedes massive exsanguination by hours to weeks. Any gastrointestinal bleeding in a patient with prior aortic surgery requires CT angiography.
Critical Pitfalls to Avoid
Relying on initial hemoglobin to assess severity: A normal hemoglobin in the emergency department does not exclude significant hemorrhage. Hemodynamic status, lactate, and clinical appearance are better early indicators. The hemoglobin will fall over the next 24 to 72 hours as hemodilution occurs.
Forgetting beta-blockers mask tachycardia: Patients on beta-blockers may not develop tachycardia despite significant blood loss. Do not be falsely reassured by a normal heart rate in these patients. Assess other signs of shock: blood pressure, mental status, lactate, urine output.
Assuming negative endoscopy excludes serious pathology: Dieulafoy lesions, angiodysplasia, and aortoenteric fistulas can all be missed on initial endoscopy. If clinical suspicion remains high or bleeding recurs, repeat endoscopy, perform CT angiography, or consider angiography.
Over-transfusing patients with variceal bleeding: Liberal transfusion in cirrhotics increases portal pressure and rebleeding risk. Target hemoglobin of 7 to 8 g/dL unless there is ongoing massive hemorrhage or significant cardiac disease. Avoid hemoglobin targets above 9 g/dL.
Forgetting antibiotics in suspected variceal bleeding: Prophylactic antibiotics significantly reduce mortality in cirrhotic patients with gastrointestinal bleeding. Start ceftriaxone empirically—do not wait for endoscopic confirmation of varices.
Delaying endoscopy in high-risk patients: Emergent endoscopy (within 12 hours) improves outcomes in hemodynamically unstable patients and those with suspected variceal bleeding. Do not delay for “optimization” if the patient can be adequately resuscitated.
Stopping all antiplatelet agents in patients with recent coronary stents: Stent thrombosis can be fatal. Consult cardiology urgently. Aspirin can often be continued; hold P2Y12 inhibitors temporarily but restart as soon as hemostasis is achieved.
Discharging without addressing the underlying cause: Achieving hemostasis is not enough. Test for Helicobacter pylori and treat if positive. Review and discontinue offending medications. Arrange follow-up endoscopy for gastric ulcers to exclude malignancy. Start secondary prophylaxis for variceal bleeding.
Key Takeaways
- Upper gastrointestinal bleeding is a medical emergency with 2% to 10% mortality overall, rising to 15% to 30% for variceal bleeding—early recognition and appropriate triage are critical
- The “Big Four” causes (peptic ulcer disease, erosive disease, varices, and Mallory-Weiss tears) account for 80% to 90% of cases—but always consider aortoenteric fistula in patients with prior aortic surgery
- Hemodynamic assessment is more reliable than initial hemoglobin—use the Shock Index (heart rate divided by systolic blood pressure) as a rapid bedside tool; greater than 1.0 indicates significant hemorrhage
- Distinguish variceal from non-variceal bleeding early—variceal bleeding requires vasoactive drugs (octreotide), prophylactic antibiotics, and specific endoscopic techniques (band ligation)
- Restrictive transfusion (target hemoglobin 7 g/dL) improves outcomes compared to liberal transfusion—this is especially important in variceal bleeding to avoid increasing portal pressure
- Risk stratification scores guide disposition: Glasgow-Blatchford 0 to 1 identifies very low-risk patients suitable for outpatient management; AIMS65 predicts mortality
- Endoscopy is diagnostic and therapeutic—timing should be within 24 hours for most patients, within 12 hours for high-risk or variceal bleeding
- Forrest classification guides management of ulcers: high-risk stigmata (Forrest Ia, Ib, IIa, IIb) require endoscopic therapy and high-dose proton pump inhibitor infusion; low-risk (IIc, III) can be managed with oral therapy and early discharge
- Address the underlying cause before discharge: test and treat Helicobacter pylori, discontinue NSAIDs, manage anticoagulation appropriately, and arrange follow-up for gastric ulcer healing
- For refractory bleeding, have a systematic approach: repeat endoscopy, consider interventional radiology for embolization, and involve surgery early for uncontrolled hemorrhage or suspected aortoenteric fistula
Quick Reference Algorithm
Systematic Approach to Upper Gastrointestinal Bleeding:
- Assess and stabilize: ABCs, two large-bore IVs, crystalloid resuscitation, type and crossmatch; calculate Shock Index
- Risk stratify: Calculate Glasgow-Blatchford score; identify red flags (hemodynamic instability, variceal bleeding, prior aortic surgery)
- Initiate empiric therapy: IV proton pump inhibitor for all; add octreotide and antibiotics if variceal bleeding suspected
- Transfuse appropriately: Restrictive strategy (hemoglobin less than 7 g/dL) in most patients; correct coagulopathy if present
- Time endoscopy correctly: Emergent (within 12 hours) for unstable or variceal; urgent (within 24 hours) for most others; consider outpatient if Glasgow-Blatchford 0 to 1
- Provide endoscopic therapy: Treat high-risk lesions with combination therapy; band ligation for esophageal varices
- Post-endoscopy care: High-dose IV proton pump inhibitor for 72 hours if high-risk stigmata; secondary prophylaxis for varices
- Address underlying cause: Helicobacter pylori testing and treatment; medication review; follow-up endoscopy for gastric ulcers
- Plan for refractory bleeding: Repeat endoscopy, interventional radiology, or surgery as indicated
- Arrange appropriate follow-up: Gastroenterology follow-up; repeat endoscopy to confirm ulcer healing; ongoing management of liver disease if present